Navigation Links
DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0
Date:10/21/2008

Web-based Software Significantly Improves Patient Recruitment Process

SAN FRANCISCO, Oct. 21 /PRNewswire/ -- DecisionView, Inc., the leading provider of software solutions to optimize clinical trial performance for life sciences companies, today announced the availability of StudyOptimizer 4.0, the latest version of its Web-based software solution. Designed to improve the patient recruitment process in clinical trials, the new StudyOptimizer 4.0 software provides significant, measurable business results.

"As clinical trials are becoming increasingly larger, more expensive and more complex, StudyOptimizer 4.0 provides additional functionality to help solve the challenges faced by enrollment planners and clinical operations worldwide," said Steve Andrade, CEO, DecisionView. "Our latest iteration significantly improves clinical trial performance and predictability, offering pharmaceutical companies with a tangible way to improve cost and efficiency."

Under development for more than a year, StudyOptimizer 4.0 represents a major milestone for DecisionView. The new product offers significant new features designed to improve user experience, performance, scalability and reliability.

"StudyOptimizer's advanced analytics and visualization combined with the wealth of research experience of our study managers, and a rejection of the 'ready, aim, fire' approach to clinical trial planning, has enabled GSK to double the frequency with which trials are completed on-time," said Alex Lancksweert, director of Business Performance Analytics at GlaxoSmithKline. "StudyOptimizer has enabled our teams to work in a more collaborative style to create robust plans grounded on empirically justified assumptions, and to streamline decision making by more effectively communicating trial progress to a dispersed study team and participating research sites."

Built atop a new and modern architecture, StudyOptimizer 4.0 includes new features such as:

-- New User Interface Framework. The new user interface is designed to streamline navigation and accelerate user adoption. A new task pane allows users to understand and execute the steps needed to complete a recruitment plan. Charts, legends, tables, columns and other UI elements can be easily hidden or resized to give users more control over the application look and feel. The new framework also includes a new caching mechanism that considerably improves response times when navigating throughout the application.

-- New Analytic Engine. StudyOptimizer 4.0 features OLAP technology that performs complex calculations and delivers analytic views into operational data. This new feature not only improves overall application performance, but also provides the foundation for StudyOptimizer's innovative visualizations of enrollment data.

-- New J2EE Application Server. A new, enterprise-class J2EE server -- built leveraging object-oriented design patterns -- delivers higher reliability, scalability, availability, and performance. It abstracts business logic from data storage and interfaces with the data warehouse and analytic engine to present information to the StudyOptimizer rich client.

-- Enhanced Administration. The StudyOptimizer Administration application provides an enhanced security model for defining access privileges and study access groups. User profiles now include new attributes, such as e-mail addresses and job titles. Integration with LDAP servers has been enhanced to import LDAP users in batch mode, either dynamically or at a scheduled time.

Due to its intrinsic service-oriented nature, this new architecture facilitates the development and release of new features in a more modular approach, allowing for more rapid and efficient innovation. The modular nature will also provide easier entry points for customers who will be able to license functionality incrementally according to their business needs.

About DecisionView

DecisionView develops innovative Web-based software solutions that enable life sciences organizations around the world to improve clinical trial performance. DecisionView improves the visibility and predictability of clinical trial performance by automating critical clinical trials processes with integrated predictive analytics, simulation and scenario modeling capabilities that deliver proven business value, including faster cycle times and reducing clinical trials costs. Granite Ventures, Partech International and Aeris Capital are primary investors in the company.

For additional information, visit http://www.decisionview.com.


'/>"/>
SOURCE DecisionView, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference
2. ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services
3. USA-ONE Interactive Unveils Visioneer OneTouch Scanning into the Docuvation Content Management Solution
4. American Airlines Unveils Largest Aircraft Branded With Susan G. Komen for the Cures Streaming Pink Ribbon
5. Medco CEO Unveils Pragmatic Blueprint for Health Care Reform; Reducing Costs by Upwards of $1 Trillion
6. Florida Hospital Unveils New Details, Name for Childrens Hospital of the Future
7. UBC scientist unveils secret of newborns first words
8. Medical Records Institute Unveils Platform for Studying Cell Phone Applications in Healthcare
9. Johnson & Johnson Unveils Olympic Games Pavilion Featuring Authentic Qin Shi Huang Terracotta Warrior Exhibit
10. LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients
11. Video: Allen Institute for Brain Science Unveils Worlds First Genome-Wide Spinal Cord Atlas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; ... WHAT: , Medical doctors and PhD scientists will speak to the press on behalf ... in support of an independent vaccine safety commission. , WHERE: , Zenger Room, ...
(Date:3/28/2017)... Conn. (PRWEB) , ... March 28, 2017 , ... ... based in Wethersfield, Conn., has relocated its corporate headquarters to a new, more ... clients. , In October 2016, Qualidigm purchased a distressed office building in ...
(Date:3/28/2017)... ... ... The Executives, Staff & Clients of MGE: Management Experts joined forces with ... Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. Petersburg Office. , ... 14 internationally in literacy. Statistically, a direct relation can be a found between illiteracy ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... ... 28, 2017 , ... Thank you to all who attended Capio Partners Winter ... event was exclusive to providers and offered an opportunity to collaborate and network with ... Manchester Grand Hyatt where attendees gathered for a lively discussion on trends and issues ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global surgical sealants ... of USD 4.5 billion by 2025, according to a ... of injured tissues post operation is a major step ... in 3% to 15% of cases and are considered ... third of postoperative deaths in patients. Surgical sealants and ...
(Date:3/27/2017)... , March 27, 2017 ... better understand Bayer and its partnering interests and activities since ... report provides an in-depth insight into the partnering activity of ... On demand company reports are prepared upon purchase to ensure ... data. The report will be delivered in PDF ...
(Date:3/27/2017)...  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the ... of common stock in an underwritten public offering under ... Securities and Exchange Commission (the "SEC"). The offering is ... be no assurance as to whether or when the ... size or terms of the offering. Cryoport also expects ...
Breaking Medicine Technology: